Table 1.

Demographic and treatment data at baseline.

Study Group	Open-label Glycine (n=10)	Placebo-controlled
		Glycine (n=4)	Placebo (n=4)
Characteristic	Mean(SD)	Mean(SD)	Mean(SD)
Age (yr)	17.3 (3.3)	15.3 (0.5)	16.5 (2.4)
Current GAF	44.3 (4.7)	40.5 (4.0)	39.0 (9.0)
	No. (%)	No. (%)	No. (%)
Male	7 (70)	3 (75)	3 (75)
White nonHispanic	6 (60)	3 (75)	2 (50)
Single	10 (100)	4 (100)	4 (100)
Prodromal syndrome
APS	10 (100)	4 (100)	4 (100)
BIPS	1 (10)	0 (0)	0 (0)
GRD	0 (0)	0 (0)	0 (0)
First degree family history
Psychosis	0 (0)	0 (0)	0 (0)
Nonpsychotic major depression	1 (10)	1 (25)	2 (50)
Nonpsychotic bipolar disorder	2 (20)	0 (0)	0 (0)
Medication use at baseline*
Antidepressants	3 (30)	1 (25)	1 (25)
Antipsychotics	0 (0)	0 (0)	0 (0)
Benzodiazepines/hypnotics	0 (0)	0 (0)	0 (0)
Mood stabilizers	0 (0)	0 (0)	0 (0)
Stimulants	0 (0)	0 (0)	0 (0)
Lifetime substance abuse/dependence
Marijuana	1 (10)	0 (0)	0 (0)
Other (except nicotine)**	1 (10)	0 (0)	0 (0)

All comparisons n.s. GAF, Global Assessment of Functioning.

^*Patients taking antidepressants, anxiolytics, mood stabilizers, or stimulants were permitted to continue these medications but not to change dose. Doses were required to be stable ≥8 weeks at baseline.

^**Other in substance abuse/dependence includes: alcohol, sedatives, opioid, cocaine, hallucinogen and other.